On Jul. 7, 2017, the U.S. Food and Drug Administration (FDA) approved Fluad Quadrivalent (influenza vaccine, adjuvanted; Seqirus) for adults 65 years and older. FLUAD QUADRIVALENT (aQIV) utilizes the same MF59 adjuvant technology as FLUAD (aTIV), designed to create a strong, broad and durable immune response.

FLUAD QUADRIVALENT included an additional strain to FLUAD, which had an extensive clinical legacy, with 114+ million doses distributed and licensure in 29 countries since it was first approved in 1997 in Italy and the U.S. in 2015.